Guggenheim raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $143 from $140 and keeps a Buy rating on the shares. The firm is updating its model following Q4 earnings and a check-in with management.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target lowered to $136 from $145 at Wells Fargo
- Rhythm Pharmaceuticals price target raised to $176 from $167 at Citizens
- Rhythm Pharmaceuticals files automatic mixed securities shelf
- Rhythm Pharmaceuticals files to sell 2.4M shares of common stock for holders
- Rhythm Pharmaceuticals: Imcivree Momentum and Bivamelanotide Pipeline Catalysts Underpin Buy Rating and $130 Target